Copaxone And Complex Generics: Difficult-To-Copy Does Not Mean Impossible

FDA’s approval of the first ANDA for an MS therapy signals the agency’s determination to find a way to get generic versions of complex drugs to market. What if any lessons does that hold for biosimilars?